GB0314682D0 - Materials and methods relating to the modulation of T cell response to soluble antigen - Google Patents

Materials and methods relating to the modulation of T cell response to soluble antigen

Info

Publication number
GB0314682D0
GB0314682D0 GBGB0314682.6A GB0314682A GB0314682D0 GB 0314682 D0 GB0314682 D0 GB 0314682D0 GB 0314682 A GB0314682 A GB 0314682A GB 0314682 D0 GB0314682 D0 GB 0314682D0
Authority
GB
United Kingdom
Prior art keywords
modulation
materials
cell response
methods relating
soluble antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0314682.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB0314682.6A priority Critical patent/GB0314682D0/en
Publication of GB0314682D0 publication Critical patent/GB0314682D0/en
Priority to PCT/GB2004/002726 priority patent/WO2005000348A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0314682.6A 2003-06-24 2003-06-24 Materials and methods relating to the modulation of T cell response to soluble antigen Ceased GB0314682D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0314682.6A GB0314682D0 (en) 2003-06-24 2003-06-24 Materials and methods relating to the modulation of T cell response to soluble antigen
PCT/GB2004/002726 WO2005000348A2 (fr) 2003-06-24 2004-06-24 Matieres et procedes concernant la modulation de la reponse des lymphocytes t a un antigene soluble

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314682.6A GB0314682D0 (en) 2003-06-24 2003-06-24 Materials and methods relating to the modulation of T cell response to soluble antigen

Publications (1)

Publication Number Publication Date
GB0314682D0 true GB0314682D0 (en) 2003-07-30

Family

ID=27637222

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0314682.6A Ceased GB0314682D0 (en) 2003-06-24 2003-06-24 Materials and methods relating to the modulation of T cell response to soluble antigen

Country Status (2)

Country Link
GB (1) GB0314682D0 (fr)
WO (1) WO2005000348A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
EP1848813B1 (fr) 2005-01-28 2013-04-10 Brigham Young University Activation de glycolipides bacteriens de cellules nkt appauvries en cd1d
CN101309705A (zh) * 2006-01-13 2008-11-19 独立行政法人理化学研究所 用于免疫疾病的预防或治疗剂以及方法
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
CA2661789C (fr) 2006-04-07 2014-06-03 The Scripps Research Institute Galactosyl-ceramides modifiees pour colorer et stimuler des lymphocytes t tueurs naturels
US7794722B2 (en) 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use
CA2678618C (fr) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation d'activite de cellule nkt avec des molecules cd1d chargees en antigene
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2483287B1 (fr) * 2007-10-12 2016-03-16 Luigi Panza Analogues de glycolipides en tant qu'immunoadjuvants
EP2058011A1 (fr) 2007-11-07 2009-05-13 Wittycell Cellule Nkt activant des antigènes et/ou médicaments à liaison gycolipids covalentyl
KR101566847B1 (ko) 2007-12-05 2015-11-06 아비박스 항원에 대한 면역 반응 증강을 위한 글리코실세라마이드의 용도
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
KR101887040B1 (ko) * 2012-06-20 2018-08-09 고쿠리츠다이가쿠호징 도쿄다이가쿠 점막 면역 부활화제 및 hpv 감염증 치료용 경구 의약 조성물
WO2014124245A1 (fr) 2013-02-08 2014-08-14 Vaccinex, Inc. Glycolipides modifiés, leurs procédés de préparation et utilisations
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
WO2014133106A1 (fr) * 2013-02-27 2014-09-04 独立行政法人理化学研究所 Médicament traitant les maladies allergiques
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
EP2952372A1 (fr) 2014-06-04 2015-12-09 AGC Glass Europe Vitrage comprenant un film à cristaux liquides
EP2955976A1 (fr) 2014-06-12 2015-12-16 AGC Glass Europe Vitrage chauffant
US11850279B2 (en) * 2016-07-13 2023-12-26 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
US20220387461A1 (en) * 2019-09-04 2022-12-08 Victoria Link Ltd Cancer vaccine
US20230203122A1 (en) * 2020-05-14 2023-06-29 Nutcracker Therapeutics, Inc. Polynucleotides comprising an antigenic payload

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer

Also Published As

Publication number Publication date
WO2005000348A2 (fr) 2005-01-06
WO2005000348A3 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
GB0314682D0 (en) Materials and methods relating to the modulation of T cell response to soluble antigen
EP1599228A4 (fr) Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
SI2368907T1 (sl) Anti-abeta protitelesa in njihova uporaba
HK1102600A1 (en) Novel anti-igf-ir antibodies and uses thereof
EP1765988A4 (fr) Cellules de presentation de nouveaux antigenes artificiels, et utilisations correspondantes
EP1482984A4 (fr) Anticorps de substitution et leurs procedes de preparation et d'utilisation
EP1578947A4 (fr) Anticorps diriges contre la phospholipase a2 et utilisations
IL178593A (en) Specific antibodies of fcγriib and methods for their use
EP1551447A4 (fr) Anticorps anti-addl et leurs utilisations
IL225633B (en) Antibodies against alpha v beta 6 and uses thereof
EP1787998A4 (fr) Anticorps et utilisation s'y rapportant
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL169638A0 (en) Soluble fcyr fusion proteins and methods of use thereof
EP1610818A4 (fr) Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
EP1740210A4 (fr) Anticorps irta-5 et utilisations de ces derniers
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
EP1699485A4 (fr) Anticorps anti-hydroxylase et utilisations
EP1689781A4 (fr) Anticorps de clycoformes de cd44 et utilisations de ceux-ci
EP1646096A4 (fr) Bloc-batterie et son procede de production
EP1638513A4 (fr) Substances insaponifiables en teneur elevee et leurs procedes d'utilisation
IL174827A0 (en) Antibodies to nik preparation and use
AU2002314887A1 (en) Gads as modifiers of the p53 pathway and methods of use
AU2003219093A1 (en) Anti-hpv-16 e7 antibodies and their use
GB0307352D0 (en) Improvements in and relating to the analysis of compounds
AU2003248879A1 (en) RABS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)